Observations placeholder
Myfortic
Identifier
019563
Type of Spiritual Experience
Background
A description of the experience
Mycophenolic acid, less accurately called mycophenolate, is an immunosuppressant drug used to prevent rejection in organ transplantation. It inhibits an enzyme needed for the growth of T cells and B cells. It was initially marketed as the prodrug mycophenolate mofetil (MMF) to improve oral bioavailability. More recently, the salt mycophenolate sodium has also been introduced. Mycophenolate mofetil is commonly marketed under the trade name CellCept ( for oral use), and mycophenolate sodium as Myfortic .
Adverse effects
Common adverse drug reactions (≥1% of patients) associated with mycophenolate therapy include diarrhea, nausea, vomiting, joint pain; infections, leukopenia, and/or anemia reflect the immunosuppressive and myelosuppressive nature of the drug. Mycophenolate sodium is also commonly associated with fatigue, headache, cough and/or breathing issues. Intravenous (IV) administration of mycophenolate mofetil is also commonly associated with thrombophlebitis and thrombosis. Infrequent adverse effects (0.1–1% of patients) include esophagitis, gastritis, gastrointestinal tract hemorrhage, and/or invasive cytomegalovirus (CMV) infection More rarely, pulmonary fibrosis or various neoplasia occur: melanoma, lymphoma, other malignancies having an occurrences of 1 in 20 to 1 in 200, depending on the type, with neoplasia in the skin being the most common site Several cases of pure red cell aplasia (PRCA) have also been reported
The U.S. Food and Drug Administration (FDA) has issued an alert that patients on mycophenolate mofetil and mycophenolic acid are at increased risk of opportunistic infections, such as activation of latent viral infections, including shingles, other herpes infections, cytomegalovirus, and BK virus associated nephropathy. In addition the FDA is investigating 16 patients that developed a rare neurological disease while taking the drug. This is a viral infection known as progressive multifocal leukoencephalopathy; it attacks the brain and is usually fatal
Mycophenolic acid is associated with miscarriage and congenital malformations when used during pregnancy.
On Jan, 04, 2017 5,291 people reported to have side effects when taking Myfortic.
Among them, 19 people (0.36%) have Hallucination
On Dec, 12, 2015: 2,871 people reported to have side effects when taking Myfortic. Among them, 106 people (3.69%) have Death.
Time on Myfortic when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 13.64% | 18.18% | 13.64% | 22.73% | 31.82% | 0.00% | 0.00% |
Gender of people who have Death when taking Myfortic :
| Female | Male | |
| Death | 36.79% | 63.21% |
Age of people who have Death when taking Myfortic :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 0.00% | 0.00% | 0.00% | 5.80% | 7.25% | 17.39% | 28.99% | 40.58% |
Top conditions involved for these people :
- Renal transplant (48 people, 45.28%)
- Liver transplant (5 people, 4.72%)
- Immunosuppression (3 people, 2.83%)
- Heart transplant (3 people, 2.83%)
- Cytomegalovirus infection (3 people, 2.83%)